Given the lack of clarity regarding the benefits of metformin in patients with type 2 diabetes mellitus who were prescribed DPP-4 inhibitors (DPP-4is), we compared KL-6 levels in patients who… Click to show full abstract
Given the lack of clarity regarding the benefits of metformin in patients with type 2 diabetes mellitus who were prescribed DPP-4 inhibitors (DPP-4is), we compared KL-6 levels in patients who were prescribed DPP-4is and in patients who were prescribed both DPP-4is and metformin. 54 patients were prescribed DPP-4is and KL-6 levels were measured in all of these patients. 25 patients were prescribed metformin. Thus, the patients were categorized into two groups: DPP-4i (DPP-4i without metformin; N = 29) and DPP-4i and met (DPP-4i with metformin; N = 25). The KL-6 levels in the DPP-4i was significantly higher than that of DPP-4i and met groups (300.76 ±155.39 vs223.96 ±73.83 U/mL, mean ±standard deviation, reference range: Disclosure Y. Shimoda: None. J. Okada: None. E. Yamada: None. S. Okada: None. M. Yamada: None.
               
Click one of the above tabs to view related content.